Radical resection of a soft tissue malignant tumor (e.g., sarcoma) of the face or scalp, where the tumor plus required excision margins measure 2 cm or greater.

Verified May 8, 2026 · 7 sources ↓

Medicare: $901.49
Work RVU: 14.88
Global, days: 90
Region: Other

Drawn from CMSFacsKzanowFastrvuAAPC

Documentation requirements

What must appear in the operative or office note to support the claim.

Source · Editorial brief grounded in 7 cited references ↓

Confirm malignant histology (biopsy report or prior pathology) — radical resection codes require a malignant indication, not benign lesion.
Record greatest tumor diameter plus the required excision margin measurement taken at time of surgery — this is the size that determines code selection.
Specify anatomic depth: subcutaneous vs. subfascial (subgaleal, intramuscular) — depth determines whether 21014/21015/21016 applies.
Document extent of resection into surrounding structures, not just lesion dimensions — supports 'radical' characterization over simple excision.
Name the closure method used; direct closure is bundled, but flap or graft reconstruction must be separately documented and coded.
If modifier 22 is used, include a specific narrative explaining why work was substantially greater than typical — tumor adherence to critical structures, prior radiation field, revision resection.

Applicable modifiers

Modifiers commonly billed with this code.

Source · AMA CPT modifier descriptors · CMS NCCI Policy Manual

22 Increased complexity 24 Unrelated E/M during global 25 Significant separate E/M 51 Multiple procedures 57 Decision for surgery 58 Staged or related 59 Distinct service 76 Repeat, same physician 77 Repeat, another physician 78 Unplanned return — related 79 Unrelated during global 80 Assistant surgeon

What this code covers

Source · Editorial summary grounded in 7 cited references ↓

CPT 21016 covers radical resection of soft tissue malignant tumors — classically sarcomas — arising from the face or scalp when the greatest tumor diameter plus the surgeon's required margin equals 2 cm or more. This is not a simple excision: the resection extends beyond the visible tumor boundaries into surrounding anatomical structures to achieve clear margins. Size is measured at the time of excision as tumor diameter plus the narrowest adequate margin, not just the lesion itself.

Code selection within the 21011–21016 family is driven by two variables: anatomic depth (subcutaneous vs. subfascial) and size threshold (under 2 cm vs. 2 cm or greater). 21016 is the highest-intensity code in the face/scalp group — radical resection, 2 cm or greater. These codes do not apply to cutaneous-origin tumors such as melanoma requiring soft tissue clearance; those belong to the 11600–11646 series. Direct closures (simple, intermediate, complex) are bundled into 21016. Separately reportable closure includes adjacent tissue transfer, skin grafts, and muscle flaps — bill those with the appropriate reconstruction code.

The 90-day global period means all routine post-op care through day 90 is bundled. Unrelated E/M services in that window need modifier 24. A separate E/M on the day of surgery requires modifier 25 if the decision for surgery was made that day. Because this procedure serves oncologic indications, pre-operative imaging (MRI, CT) and pathology for margin assessment are separately billable and frequently part of the episode — document medical necessity for each independently.

RVU & reimbursement

Component RVUs and Medicare national rate. Actual payment varies by GPCI locality.

Source · CMS Physician Fee Schedule, RVU26A · January 2026

Work RVU vs. total RVU

The work RVU (14.88) is the surgeon's own effort — the figure physician pay and productivity targets are built on. The total RVU (26.99) adds practice overhead and malpractice, and is what drives the Medicare payment below.

Work RVU	14.88
Practice expense RVU	9.36
Malpractice RVU	2.75
Total RVU	26.99
Medicare national rate	$901.49
Global period	90 days

Payment by site of service

Medicare pays different rates by setting. HOPD typically pays substantially more than ASC for the same procedure.

Source · CMS OPPS Addendum B·ASC HCPCS payment rates·2026

Setting	Medicare rate (national)
Office (PFS non-facility) Procedure performed in physician's office	$901.49
HOPD (APC 5073) Hospital outpatient department	$2,967.63
ASC (PI G2) Ambulatory surgical center (freestanding)	$1,248.36

Common denial reasons

The recurring reasons claims for CPT 21016 get rejected.

Source · Editorial brief grounded in CMS NCCI edits, AAOS coding appeals, and cited references ↓

Code selected from 11600–11646 series instead of 21016 when the tumor is deep soft tissue, not cutaneous origin — auditors flag mismatched code family.
Size measurement documented as tumor diameter only, without including margins — payers deny or downcode when the combined measurement isn't recorded.
Radical resection billed for a benign lesion; 21016 requires a malignant indication supported by pathology or clinical diagnosis.
Reconstruction (adjacent tissue transfer, graft) billed without documentation that closure type exceeded direct repair — bundling edits trigger if operative note doesn't specify.
E/M service billed same-day without modifier 25, causing the visit to bundle into the surgical package.

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 7 cited references ↓

01How is tumor size determined for 21016 vs. 21015?

Measure the greatest tumor diameter plus the narrowest margin required for complete excision at the time of surgery. If that combined measurement is 2 cm or greater, use 21016. Under 2 cm is 21015. The measurement is made intraoperatively, not from pre-op imaging.

02Can 21016 be billed for a melanoma resection on the scalp?

No. Malignant tumors of cutaneous origin — including melanoma requiring excision of underlying soft tissue — are reported with codes 11600–11646. CPT 21016 applies to deep soft tissue malignancies such as sarcomas, not cutaneous-origin tumors.

03Is reconstruction separately billable with 21016?

Direct closure (simple, intermediate, complex) is bundled into 21016 and cannot be separately reported. Adjacent tissue transfer, split- or full-thickness skin grafts, and muscle flaps are separately reportable — document the specific reconstruction type in the operative note.

04What modifier applies when a related complication requires return to the OR within the 90-day global?

Use modifier 78 for an unplanned return to the OR for a complication related to the original procedure. Modifier 79 applies only if the return procedure is unrelated to the original surgery. Do not invert these.

05When is modifier 22 appropriate for 21016?

When the work is substantially greater than typical for the code — for example, resecting a recurrent sarcoma densely adherent to facial nerve branches or operating in a previously irradiated field. The operative note must explicitly describe the additional complexity; a generic statement is not sufficient for most payers.

06Does 21016 differ from subfascial excision codes 21013 and 21014?

Yes. 21013 and 21014 are subfascial excisions, appropriate for benign or less aggressive tumors at depth. 21016 is radical resection for malignant tumors requiring wider clearance into surrounding structures. The distinction is both the malignant indication and the extent of resection, not depth alone.

Sources & references

Editorial content was developed using the following public sources. Last verified May 8, 2026.

Mira Scribe

Mira's AI scribe captures tumor location on the face or scalp, anatomic depth (subcutaneous vs. subfascial), the combined tumor-plus-margin measurement taken at excision, surgical extent into adjacent structures, closure type, and laterality from the operative dictation. That prevents the two most common 21016 audit flags: a size measurement that omits margins and an operative note that fails to document why the resection qualifies as radical rather than simple excision.

See how Mira captures CPT 21016 documentation